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Management of Benign Prostatic Hyperplasia – South 
African Urological Association Guideline
1. Introduction
Benign prostatic hyperplasia (BPH) is one of the most 
common conditions affecting older men. Strictly speaking, 
BPH is a histological diagnosis, and the term benign prostatic 
enlargement (BPE) is used when there is detectable enlargement 
of the prostate that is clinically not malignant. As a result of 
BPH, as many as 1 in 3 men over the age of 45 experience 
bothersome lower urinary tract symptoms (LUTS) that affect 
daily activities and sleep patterns. This symptom complex was 
previously referred to as prostatism. LUTS are divided into 
storage symptoms, including daytime frequency and nocturia, 
and voiding symptoms, including hesitancy, decreased flow rate 
and post-micturition dribbling. LUTS may also be due to other 
causes of bladder outflow obstruction (BOO), such as a urethral 
stricture, or conditions causing neurological dysfunction of the 
bladder detrusor muscle or sphincter mechanisms.  
Hyperplastic changes in the prostate begin in the 3rd decade 
of life and by 60 years of age nearly half of all men have 
symptoms of BPH. These guidelines are specifically designed 
for clinical use by family practitioners to give an overview of 
the assessment and management options available for men with 
LUTS caused by BPH.
2.  Diagnostic evaluation of men with 
LUTS
2.1  History
General medical history should include specific questions about 
the presence of any urinary symptoms and a family history 
of any cancers. Patients who request screening for BPH or 
prostate cancer should be assessed, but general screening of 
asymptomatic men is not recommended.
There are six focused questions related to specific LUTS that 
should be asked:
• Dysuria – ‘Do you have pain or burning on urination?’
• Nocturia – ‘How often do you wake at night to pass urine?’
• Hesitancy – ‘Do you have difficulty starting urination?’
• Urgency – ‘Do you ever have to rush to the toilet to urinate?’
• Incontinence – ‘Do you ever wet your pants?’
• Haematuria – ‘Have you ever seen blood in your urine?
The use of a symptom scoring system such as the 
International Prostate Symptom Score (IPSS) (Table I) is useful to 
determine how much the patient is bothered by his symptoms, 
and it provides an essential baseline to evaluate the success of 
any treatment. 
Keeping a voiding diary or frequency/volume chart is useful 
in interpreting the patient’s symptoms, particularly if nocturia is 
a dominant symptom. 
2.2  Examination
•  General examination, including a focused neurological 
assessment.
•  Specific examination of the abdomen, genitalia and a digital 
rectal examination (DRE) are mandatory in the assessment of 
men with LUTS and none of these should be omitted.
2.3  Recommended investigations
1. Dipstick urinalysis testing. Patients with haematuria should 
be referred for further evaluation.
2. Prostate-specific antigen (PSA). 
Age-adjusted PSA normal values used:
• < 50 years old   PSA < 2.5 ng/ml
• 51 - 65 years   PSA < 4.0 ng/ml
• > 65 years   PSA < 6.5 ng/ml.
PSA velocity: If > 20% increase in PSA in 1 year – refer.
3. Serum creatinine.
2.4  Optional investigations 
These are usually performed by a urologist on the basis of 
specific clinical indications.
• Urinary flow rate recording
• Post-void residual urine measurement
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• Ultrasound of upper tracts and/or prostate
• Urine cytology
• Pressure/flow urodynamic studies
• Urethro-cystoscopy.
3.  Treatment recommendations
If any of the following is found on initial evaluation of LUTS, 
patients should be referred for specialist opinion:
• Suspicious DRE  
• Recurrent urinary tract infection
• Haematuria   
• Palpable bladder
• Abnormal PSA  
• Neurological disease
• Pain – suprapubic, perineal, or low lumbar pain. 
3.1  Watchful waiting/reassurance
This is the preferred management strategy for patients with 
mild LUTS. Patients are monitored by their doctor but receive 
no medical or surgical therapy. Patients considered for this 
management must have low impact of their symptoms on 
their quality of life (IPSS score < 7) and must have no objective 
evidence of BPH complications (infection, stones, haematuria, 
renal failure or chronic retention).
Patients should be informed about lifestyle adaptations 
including selected restriction of fluid intake, decreasing 
Table I. IPSS – International Prostate Symptom Score
Name:                              
Not at
all
Under
¼ the
time
Under
½ the
time ½ the time
Over
½ the
time
Almost
always
Your
score
1. Incomplete emptying
Over the last month, how often have you had a sensation 
of not emptying your bladder completely after you 
finished urinating? 
0 1 2 3 4 5
2. Frequency
Over the last month, how often have you had to urinate 
again less than 2 hours after you finished urinating?
0 1 2 3 4 5
3. Intermittency
Over the last month, how often have you found you 
stopped and started again several times when you 
urinated? 
0 1 2 3 4 5
4. Urgency
Over the last month, how often have you found it 
difficult to postpone urination? 
0 1 2 3 4 5
5. Weak stream
Over the last month, how often have you had a weak 
urinary stream? 
0 1 2 3 4 5
6. Straining
Over the last month, how often have you had to push or 
strain to begin urination? 
0 1 2 3 4 5
None 1 time 2 times 3 times 4 times 5+ times
Your 
score
7. Nocturia
Over the last month, how many times did you most 
typically get up to urinate from the time you went to bed 
at night until the time you got up in the morning?
0 1 2 3 4 5
Total IPSS Score
Delighted Pleased
Mostly
satisfied
Mixed
Mostly
dissatisfied
Unhappy Terrible
Your 
Score
Quality of life due to urinary symptoms
If you were to spend the rest of your life 
with your urinary condition just the way it 
is now, how would you feel about that?
0 1 2 3 4 5 6
5
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caffeine and alcohol intake, and behavioural modifications 
such as double voiding, lengthening the voiding intervals and 
avoiding constipation.
Patients should also be reassured about the absence 
of prostate cancer, and that progression of LUTS or the 
development of complications due to BPH is not inevitable. 
They should be followed up at yearly intervals.
3.2  Medical treatment
Medical therapies for LUTS due to BPH, while not as 
efficacious as surgical therapies, still provide adequate 
symptom relief in many patients and are associated with fewer 
adverse events. Patients selected for medical treatment include 
those with mild to moderate symptoms (IPSS score 7 - 19) 
who are bothered by these symptoms, and those with severe 
symptoms (IPSS score > 19). Ideally, patients should have a 
urinary flow rate measurement before commencing medical 
treatment, because virtually all clinical trials showing efficacy 
of medical treatment were performed in men with a peak flow 
rate between 5 and 15 ml/sec. Men with severe LUTS and a 
peak flow rate above 15 ml/sec are less likely to have BOO, 
and ideally require pressure-flow studies to prove the existence 
of outflow obstruction before treatment is given. 
Before commencing medical treatment, first attend to any 
modifiable factors: concomitant drugs, regulating fluid intake, 
lifestyle and dietary modifications. 
3.2.1 Alpha-adrenergic receptor antagonists (alpha-
blockade)
Alpha-blockers act by inhibiting alpha-1-adrenergic mediated 
contraction of prostatic smooth muscle, thus relieving bladder 
outlet obstruction. One-third of men do not show significant 
symptom reduction and there is no point in continuing the use 
of the drugs beyond 1 month if the patient does not respond. 
The most advantageous subtype selectivity profile of these 
drugs has not been established.
Alfuzosin, doxazosin, tamsulosin and terazosin are all 
appropriate treatments for LUTS secondary to BPH, and have 
similar clinical effectiveness. There are slight differences in the 
adverse event profiles of these agents. The main adverse events 
associated with this class of drugs are orthostatic hypotension, 
dizziness, tiredness, nasal congestion and ejaculatory problems.
Alfuzosin and tamsulosin are more uro-selective alpha-1-
blockers than doxazosin and terazosin. Tamsulosin is more 
likely to cause ejaculatory dysfunction (5%) than the other 
alpha-blockers. This is reversible on discontinuation of the 
drug. These two drugs have been shown to be safe when used 
in combination with PDE-5 (phospho-diesterase-5) inhibitors 
which are used for the treatment of erectile dysfunction (ED). 
Doxazosin and terazosin are available in different dose 
strengths and efficacy is dose-dependent. Doxazosin should be 
used with caution in men with hypertension and cardiac risk 
factors as there is a higher incidence of reported congestive 
heart failure in this group. These two drugs have not been 
shown to be safe when used in conjunction with PDE-5 
inhibitors.
Prazosin and phenoxybenzamine are NOT recommended in 
the treatment of LUTS secondary to BPH.
Alpha-blockers are not appropriate single-agent therapy for 
hypertension; patients with LUTS and hypertension should 
therefore also be treated with more appropriate agents for 
management of their hypertension.
3.2.2 5-alpha-reductase inhibitors
The 5-alpha-reductase inhibitors finasteride and dutasteride 
are appropriate treatments for patients with LUTS associated 
with prostatic enlargement secondary to BPH. They reduce 
prostate volume and improve symptom scores and flow rates. 
They are not indicated in men with normal-sized prostates and 
are more effective in patients with prostate volumes > 30 ml 
and/or PSA readings > 1.5 ng/ml. They are less effective than 
alpha-blockers in relieving LUTS, and their maximum effect is 
only seen after 6 months of therapy. Patients with LUTS that 
are not bothersome can be offered these drugs to prevent the 
progression of BPH and the development of complications such 
as urinary retention. They are also effective for the treatment of 
haematuria due to BPH. 
Side-effects of the drugs are minimal and mainly related to 
sexual function (decreased libido in 6% and ED in 8%). These 
do not increase with time. Serum PSA levels are lowered by 
these drugs to 50% of baseline value, but the progressive 
increase in PSA caused by prostate cancer is not suppressed, so 
the detection of prostate cancer by serial PSA monitoring is not 
compromised, despite the lowered actual PSA values.
3.2.3 Combination therapy
The combination of an alpha-adrenergic receptor blocker 
and a 5-alpha-reductase inhibitor is an appropriate and 
effective therapy for patients with LUTS associated with 
BPE. Combination therapy lowers the incidence of urinary 
retention and the rate of surgical intervention in these patients. 
Discontinuation of the alpha-blocker after 6 - 12 months 
of treatment results in little or no worsening of symptoms. 
Potential benefits should be weighed against the increased cost 
of combination therapy to the patient.
3.2.4 Phytotherapeutic agents
While popular in many parts of the world, there is no 
objective evidence to demonstrate the efficacy, mode of action 
or biological effect of these agents and their use cannot be 
recommended.
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3.2.5 Medications to avoid or use with caution in patients 
with BPH
•  Testosterone – metabolised to dihydrotestosterone (DHT), 
known to cause prostate enlargement and growth.
•  Alpha-adrenergic agonists – cause bladder neck contraction 
and may compromise bladder emptying. These include 
pseudo-ephedrine, ephedrine, and phenylephrine.
•  Anticholinergic agents – may decrease detrusor 
contractility resulting in acute urinary retention.  These 
include antispasmodics and anti-parkinsonian agents (e.g. 
benztropine, trihexyphenidyl) as well as those commonly 
used for treatment of overactive bladder symptoms: 
oxybutynin, tolterodine, darifenacin, solifenacin, trospium 
and propiverine. 
•  Drugs with significant anticholinergic side-effects – may 
decrease detrusor contractility, resulting in acute retention. 
These include antihistamines, tricyclic antidepressants and 
phenothiazines. 
•  Diuretics – polyuria, secondary to high-dose therapy, may 
present as urinary frequency and nocturia.
3.3  Minimally invasive therapies (MIT)
In the South African context MIT are not widely available 
due to cost restrictions and availability. However, they have 
defined roles and are used internationally. These therapies lend 
themselves to outpatient procedures under conscious sedation 
or local anaesthesia, and are suitable for high-risk patients unfit 
for anaesthetic, patients on continuous anticoagulation therapy 
and patients wishing to retain ejaculatory function. These 
therapies include:
• Transurethral microwave thermotherapy (TUMT)
• Transurethral needle ablation (TUNA)
• Intra-prostatic stents
• Laser vaporisation.
3.4  Emerging/experimental therapy
• Botulinum toxin (Botox) intraprostatic injections
• Absolute ethanol intraprostatic injections
• High-intensity focused ultrasound (HIFU)
• Plasmakinetic tissue management system
• Water-induced thermotherapy (WIT).
3.5  NOT RECOMMENDED
• Balloon dilatation of prostate
• Urethral dilatation.
3.6  Surgical treatment
Surgical intervention is an appropriate treatment for men with 
moderate to severe LUTS and recommended for those who 
develop complications of BPH such as: 
• Acute urinary retention refractory to alpha-blockade
• Recurrent urinary retention
•  Chronic urinary retention with a palpable bladder (without 
discomfort)
• Recurrent urinary tract infections
• Bladder stones
• Upper tract dilatation
• Renal insufficiency
•  Recurrent macroscopic haematuria. 
   Optional surgical indications include:
• Bladder diverticulum
• Large post-void residual volume.
The following surgical treatment modalities can be 
recommended: 
•  Transurethral resection of the prostate (TURP) – suitable for 
prostates > 20 - 30 cm3 volume
•  Transurethral incision of the prostate (TUIP) – suitable for 
prostate volume < 20 - 30 cm3  
•  Transurethral vaporisation of the prostate (TUVP) – 
comparable to TURP
•  Open prostatectomy (retropubic/transvesical prostatectomy) 
– large prostates > 50 - 100 cm3
• Holmium laser enucleation of the prostate (HOLEP).
All the recommended surgical modalities are more or less 
equivalent with regard to outcome and efficacy. Retrograde 
ejaculation is less common after TUIP, whereas blood loss is 
greater with open prostatectomy.
4. Statements
This Guideline has the approval of the South African 
Urological Association. 
The preparation of the Guideline was made possible through 
an educational grant by Sanofi Aventis.
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Recommended Tests:
- RELEVANT MEDICAL HISTORY
- ASSESSMENT OF LUTS
  SYMPTOM SEVERITY AND
  BOTHER (IPSS SCORE)
- PHYSICAL EXAMINATION
   INCLUDING DRE
- URINALYSIS
- SERUM PSA
- FREQUENCY - VOLUME CHART
LUTS
CAUSING LITTLE 
OR NO BOTHER
REASSURANCE 
AND FOLLOW-UP
Complicated LUTS:
- SUSPICIOUS DRE
- HAEMATURIA
- ABNORMAL PSA
- PAIN
- INFECTION
- PALPABLE BLADDER
- NEUROLOGICAL
   DISEASE
BOTHERSOME LUTS
Standard Treatment
- ALTER MODIFIABLE FACTORS
   • DRUGS
   • FLUID & FOOD INTAKE
- LIFESTYLE ADVICE
- BLADDER TRAINING
Drug Treatment
FAILURE SUCCESS IN 
RELIEVING 
BOTHERSOME 
LUTS:
CONTINUE
TREATMENT
REFER FOR SPECIALISED MANAGEMENT
INITIAL MANAGEMENT OF LUTS IN MEN
        
